[Aphobazol--new selective anxyolytic drug].

A standardized clinical and pharmacological trial of the peculiarities of action and efficacy of aphobazol, a new anxyolytic with non-benzodiazepine structure, has been conducted. An effect of the drug on different anxiety disorders has been studied. It is shown that combined anxyolytic and activating action exerted the main effect. The best efficacy of aphobazol was found in anxiety disorders of "simple" structure. In more complicated anxiety disorders, aphobazol efficacy depended on the correlation between clinical appearances of deeper registers and anxiety affect. The best results have been achieved in patients with acute anxiety-phobic disorders, in the structure of which sensible anxiety with episodes of generalization, dominating vivid ideas, sensibly saturated phobias with pronounced autonomic disorders and senestalgias prevailed. In case of chronic disease course, with formation of more inert, "complex" in structure and deep by register psychopathological disorders (cognitive character of anxiety, appearances of agoraphobia and avoidance behavior, heteronomous body sensations and hypochondriac activity), the efficacy of aphobazol treatment was significantly lower. In this case a therapy combined with selective inhibitors of serotonin reuptake and neuroleptics is needed.